A61L27/46

CONTROLLABLE DEGRADATION, FILLING-TYPE COMPLEX BONE IMPLANT OF MULTIVARIANT AMINO ACID POLYMER-ORGANIC CALCIUM/PHOSPHORUS SALTS, AND PREPRATION METHOD THEREOF
20170340776 · 2017-11-30 ·

The present invention relates to the controllable degradation, filling-type complex bone implant of multivariant amino acid polymer-organic calcium/phosphorus salts, as well as to the preparative method thereof. The complex bone implant is consisted of multivariant amino acid polymers and medically acceptable organic calcium/phosphorus salts, while the content of organic calcium/phosphorus salts is 20-90% based on the total mass of composite material; the multivariant amino acid polymer is polymerized by ε-aminocaproic acid and at least two other amino acids, in which the molar content of ε-aminocaproic acid is at least 50% of the total molar quantity of amino acid polymers, while the amounts of other amino acids are at least 0.5% of the total molar quantity of amino acid polymers.

CONTROLLABLE DEGRADATION, FILLING-TYPE COMPLEX BONE IMPLANT OF MULTIVARIANT AMINO ACID POLYMER-ORGANIC CALCIUM/PHOSPHORUS SALTS, AND PREPRATION METHOD THEREOF
20170340776 · 2017-11-30 ·

The present invention relates to the controllable degradation, filling-type complex bone implant of multivariant amino acid polymer-organic calcium/phosphorus salts, as well as to the preparative method thereof. The complex bone implant is consisted of multivariant amino acid polymers and medically acceptable organic calcium/phosphorus salts, while the content of organic calcium/phosphorus salts is 20-90% based on the total mass of composite material; the multivariant amino acid polymer is polymerized by ε-aminocaproic acid and at least two other amino acids, in which the molar content of ε-aminocaproic acid is at least 50% of the total molar quantity of amino acid polymers, while the amounts of other amino acids are at least 0.5% of the total molar quantity of amino acid polymers.

BIO-NANOCOMPOSITE FOR BONE TISSUE ENGINEERING
20230181798 · 2023-06-15 ·

This disclosure describes bone tissues engineered from a casted bio-nanocomposite comprising chitosan crosslinked with citric acid to cellulose nanocrystals (CNC) where the amount of CNC used was as high as 29.4%. The nanocomposite showed proper characteristics of a bone mimicking structure. Different layers of the bio-nanocomposite showed an average pore size of greater than 26 micrometers in diameter; a porosity of about 90%, firm structure, maximum bioactivity as measured by deposition of calcium phosphate from simulated body fluid (SBF) solution (gaining weight more than 20% after 3 days), decreased rate of in vitro degradation in PBS (7-60 days), about 10% after 7 days, and acceptable bone cell viability (greater than 80%) in 2D and 3D cultures. The compression modulus of the bio-nanocomposites increased about 4 times and exhibited very small changes in size during the swelling process compared to control.

BIO-NANOCOMPOSITE FOR BONE TISSUE ENGINEERING
20230181798 · 2023-06-15 ·

This disclosure describes bone tissues engineered from a casted bio-nanocomposite comprising chitosan crosslinked with citric acid to cellulose nanocrystals (CNC) where the amount of CNC used was as high as 29.4%. The nanocomposite showed proper characteristics of a bone mimicking structure. Different layers of the bio-nanocomposite showed an average pore size of greater than 26 micrometers in diameter; a porosity of about 90%, firm structure, maximum bioactivity as measured by deposition of calcium phosphate from simulated body fluid (SBF) solution (gaining weight more than 20% after 3 days), decreased rate of in vitro degradation in PBS (7-60 days), about 10% after 7 days, and acceptable bone cell viability (greater than 80%) in 2D and 3D cultures. The compression modulus of the bio-nanocomposites increased about 4 times and exhibited very small changes in size during the swelling process compared to control.

BIO-NANOCOMPOSITE FOR BONE TISSUE ENGINEERING
20230181798 · 2023-06-15 ·

This disclosure describes bone tissues engineered from a casted bio-nanocomposite comprising chitosan crosslinked with citric acid to cellulose nanocrystals (CNC) where the amount of CNC used was as high as 29.4%. The nanocomposite showed proper characteristics of a bone mimicking structure. Different layers of the bio-nanocomposite showed an average pore size of greater than 26 micrometers in diameter; a porosity of about 90%, firm structure, maximum bioactivity as measured by deposition of calcium phosphate from simulated body fluid (SBF) solution (gaining weight more than 20% after 3 days), decreased rate of in vitro degradation in PBS (7-60 days), about 10% after 7 days, and acceptable bone cell viability (greater than 80%) in 2D and 3D cultures. The compression modulus of the bio-nanocomposites increased about 4 times and exhibited very small changes in size during the swelling process compared to control.

Moldable bone graft compositions

The present disclosure relates to compositions useful in synthetic bone graft applications. Particularly, the disclosure teaches moldable bone graft compositions, methods of making the compositions, and methods of utilizing the same.

Moldable bone graft compositions

The present disclosure relates to compositions useful in synthetic bone graft applications. Particularly, the disclosure teaches moldable bone graft compositions, methods of making the compositions, and methods of utilizing the same.

Moldable bone graft compositions

The present disclosure relates to compositions useful in synthetic bone graft applications. Particularly, the disclosure teaches moldable bone graft compositions, methods of making the compositions, and methods of utilizing the same.

DOUBLE-LAYER OSTEOCHONDRAL TISSUE REPAIR STENT AND PREPARATION METHOD THEREFOR

Provided in the present application is a preparation method for a double-layer osteochondral tissue repair stent, comprising: formulating a first feed solution, the first feed solution comprising recombinant collagen, sodium hyaluronate, and hydroxyapatite; formulating a second feed solution, the second feed solution comprising recombinant collagen and sodium hyaluronate; freeze-drying the first feed solution and the second feed solution and forming a gel-like double-layer structure; and adding the gel-like double-layer structure into a crosslinking agent for crosslinking. The present method also relates to a double-layer osteochondral tissue repair stent, comprising: a first layer composed of raw materials including recombinant collagen, sodium hyaluronate, and hydroxyapatite; and a second layer composed of raw materials including recombinant collagen and sodium hyaluronate. The double-layer osteochondral tissue repair stent prepared by the present application has excellent mechanical properties, good biocompatibility, and a suitable degradation rate and, after degradation, the stent material can be reused as raw material for the formation of new bone, thus implementing osteochondral tissue repair.

DOUBLE-LAYER OSTEOCHONDRAL TISSUE REPAIR STENT AND PREPARATION METHOD THEREFOR

Provided in the present application is a preparation method for a double-layer osteochondral tissue repair stent, comprising: formulating a first feed solution, the first feed solution comprising recombinant collagen, sodium hyaluronate, and hydroxyapatite; formulating a second feed solution, the second feed solution comprising recombinant collagen and sodium hyaluronate; freeze-drying the first feed solution and the second feed solution and forming a gel-like double-layer structure; and adding the gel-like double-layer structure into a crosslinking agent for crosslinking. The present method also relates to a double-layer osteochondral tissue repair stent, comprising: a first layer composed of raw materials including recombinant collagen, sodium hyaluronate, and hydroxyapatite; and a second layer composed of raw materials including recombinant collagen and sodium hyaluronate. The double-layer osteochondral tissue repair stent prepared by the present application has excellent mechanical properties, good biocompatibility, and a suitable degradation rate and, after degradation, the stent material can be reused as raw material for the formation of new bone, thus implementing osteochondral tissue repair.